BCAA
Evidence Fact Sheet
Branched-Chain Amino Acids · Leucine + Isoleucine + Valine
Branched-chain amino acids (leucine, isoleucine, valine, typically 2:1:1) are dietary-supplement amino acids studied for muscle-protein-synthesis signalling (leucine/mTORC1), exercise recovery, aging muscle, and hepatic encephalopathy. Evidence is mixed: HE benefit in cirrhosis but negligible standalone performance gains. Permitted supplement (US/EU/CN/BR); no authorized health claim.
Also known as: Branched Chain Amino Acids · BCAAs · Leucine-Isoleucine-Valine 2:1:1
Overview
BCAA refers to the three branched-chain essential amino acids — leucine, isoleucine and valine — usually supplied as a 2:1:1 blend. Mechanistically, leucine is the principal trigger of mTORC1 signalling that upregulates skeletal-muscle protein synthesis, and the three amino acids are oxidised peripherally in muscle (via BCKDH) rather than cleared by the liver, providing a muscle-localised fuel and ammonia-handling substrate during exercise. Common ergogenic research doses are 5-20 g/day at a 2:1:1 ratio (with at least ~2.5-3 g leucine per serving to approach the leucine threshold); a key caveat is that standalone BCAA is generally inferior to complete EAA or whole-protein intake for maximal protein synthesis because the other essential amino acids become rate-limiting. It is a permitted dietary-supplement ingredient under US DSHEA, EU Directive 2002/46/EC, China GB 14880-2012 and Brazil ANVISA frameworks, but carries no FDA- or EFSA-authorized health claim (EFSA rejected the exercise/muscle/immune claims). Educational information only; not intended to diagnose, treat, cure or prevent any disease.
Mechanism of Action
Leucine is the principal trigger of mTORC1 signalling, activating S6K1/4E-BP1 to upregulate skeletal-muscle protein synthesis · Oxidised peripherally via branched-chain ketoacid dehydrogenase (BCKDH) rather than the liver, providing a muscle-localised amino-acid fuel/anaplerotic substrate during exercise · Modulates the plasma BCAA:tryptophan ratio, hypothesised to attenuate central-fatigue serotonin synthesis (mechanistic) · Supports nitrogen handling / ammonia disposal in muscle as an alternative to hepatic urea-cycle clearance
Body systems: MUSCLE · METABOLISM
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — BCAA is not characterized as a treatment for any disease.
Hepatic Encephalopathy in Cirrhosis
Meta-analysis supported- RR 0.79hepatic encephalopathy · 95% CI 0.64-0.96
- 18 trials934 adults pooled
- RR 0.89all-cause mortality · CI 0.71-1.12
In the most recent Cochrane meta-analysis of cirrhosis patients, oral BCAA was associated with a reduction in hepatic encephalopathy versus control, though the certainty of the evidence was rated low. Notably, BCAA showed little to no effect on all-cause mortality (very low certainty), an honest mixed signal within the same review. This is a clinical-population finding, not a claim for healthy users.
Reported effect: BCAAs reduce hepatic encephalopathy (RR 0.79, 95% CI 0.64 to 0.96; 18 studies, 934 participants; low-certainty evidence); little to no effect on all-cause mortality (RR 0.89, 95% CI 0.71 to 1.12; 17 studies, 867 participants; very low-certainty evidence).
“The evidence suggests that BCAAs reduce hepatic encephalopathy (RR 0.79, 95% CI 0.64 to 0.96; 18 studies, 934 participants; low-certainty evidence). ... BCAAs may have little to no effect on all-cause mortality compared with the control interventions, but the evidence is very uncertain (RR 0.89, 95% CI 0.71 to 1.12; 17 studies, 867 participants; very low-certainty evidence).”
Source: PMID 41542879 · Aamann 2026 · Cochrane Database Syst Rev
Athletic Performance & Muscle Soreness
Null / no benefit Meta-analysis supported- 24 studiesathletes · systematic review
- negligibleperformance & body composition
A systematic review of BCAA supplementation in athletes found that, although BCAAs tend to activate anabolic signalling, the benefits on performance and body composition were negligible. Resistance-exercise studies did show attenuated muscle soreness after exercise, while endurance findings were inconsistent — and most studies did not report total daily protein intake, so even the soreness signal should be read with caution. This is the central honest negative for standalone BCAA as an ergogenic aid.
Reported effect: From 2298 records, 24 studies met inclusion; benefits on performance and body composition were negligible; BCAAs attenuated muscle soreness after exercise in resistance participants (no pooled numeric effect size reported).
“24 studies met the inclusion criteria. Although BCAAs tended to activate anabolic signals, the benefits on performance and body composition were negligible. On the other hand, studies that included resistance participants showed that BCAAs attenuated muscle soreness after exercise, while in endurance sports the findings were inconsistent.”
Source: PMID 36235655 · Martinho 2022 · Nutrients
Sarcopenia / Muscle in Older Adults (Leucine-Enriched)
Meta-analysis supported- 3 studies637 patients · sarcopenia
A meta-analysis of whey protein, leucine and vitamin D supplementation in sarcopenia patients found appendicular muscle mass significantly improved versus control, regardless of whether a physical-exercise program was added. However, handgrip strength and SPPB physical-function scores only improved significantly when supplementation was combined with exercise, not with supplementation alone. Note this is a leucine-plus-complete-protein combination, not standalone BCAA. No pooled numeric effect size was reported in the abstract.
Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.
“A total of three studies including 637 patients reported the effectiveness of using whey protein, leucine, and vitamin D supplementation in patients with sarcopenia. ... appendicular muscle mass significantly improved in the experimental group compared to the control group ... when physical exercise was not combined, there was no significant improvement in the handgrip strength and SPPB scores of patients with sarcopenia”
Source: PMID 36771225 · Chang 2023 · Nutrients
Muscle Mass & Physical Function in Older Adults (RCT)
RCT supported- 0.17 kgappendicular muscle mass · P=.045
- -1.01 secondschair-stand test · P=.018
- 380 adults13-week RCT
In the PROVIDE randomized, double-blind trial of sarcopenic older adults, a vitamin D and leucine-enriched whey protein supplement increased appendicular muscle mass and improved chair-stand (sit-to-stand) performance versus control over 13 weeks. Handgrip strength and the SPPB improved in both groups with no significant between-group difference — a partial result. This product is a leucine-enriched complete-protein formula, not isolated BCAA.
Reported effect: Active group gained more appendicular muscle mass, between-group effect 0.17 kg (0.004-0.338), P = .045; chair-stand test between-group effect -1.01 seconds (-1.77 to -0.19), P = .018; handgrip and SPPB no significant between-group difference (n=380, 13 weeks).
“The active group gained more appendicular muscle mass than the control group, between-group effect: 0.17 kg (0.004-0.338), P = .045. ... The active group improved more in the chair-stand test compared with the control group, between-group effect (95% confidence interval): -1.01 seconds (-1.77 to -0.19), P = .018. ... Handgrip strength and SPPB improved in both groups without significant between-group differences.”
Source: PMID 26170041 · Bauer 2015 · J Am Med Dir Assoc
Muscle / Sarcopenia in Cirrhosis (RCT — Null)
Null / no benefit RCT supported- p = 0.29grip strength · MAD -0.15 kg
- p = 0.22upper-limb lean mass
- 150 volunteers12-month RCT
A 12-month double-blind randomized controlled trial in cirrhosis found that BCAA supplementation did not improve grip strength or upper-limb lean mass compared with a whey protein supplement, with neither primary outcome reaching significance. This is a clear honest negative: in this population, BCAA offered no measurable advantage over whey for muscle strength, mass, performance or physical frailty.
Reported effect: No significant between-group difference in grip strength (MAD -0.15 kg [-0.37; 0.06], p = 0.29) or upper limb lean mass (1.7 kg [-0.2; 3.6], p = 0.22) at 12 months; n=150 (74 BCAA, 76 control).
“No significant between-group difference was found in grip strength (MAD -0.15 kg [-0.37; 0.06], p = 0.29) or upper limb lean mass (1.7 kg [-0.2; 3.6], p = 0.22) at 12 months. ... BCAA supplementation did not improve measures of muscle strength, mass or performance or physical frailty compared to a whey protein supplement”
Source: PMID 38404263 · Hey 2024 · Aliment Pharmacol Ther
Exercise Substrate Metabolism & Post-Exercise Fatigue (RCT)
RCT supported- p < 0.05fat oxidation & cycling efficiency
- p < 0.001lower post-exercise insulin
- 11 active malesdouble-blind crossover
In a small double-blind crossover trial in active young males, BCAA supplementation significantly raised fat oxidation during constant-load exercise, increased carbohydrate oxidation and cycling efficiency during a time-to-exhaustion test, and reduced perceived post-exercise fatigue (VAS). Blood ammonia and post-exercise insulin were also significantly lower with BCAA. The sample is small (n=11), so these are exploratory mechanistic signals rather than performance-outcome proof.
Reported effect: Fat oxidation rate significantly higher after 20 and 30 min of constant-load exercise (p < 0.05); cycling efficiency during TTE significantly improved (p < 0.05); VAS fatigue significantly decreased post-exercise (p < 0.05); insulin significantly lower post-exercise (p < 0.001); n=11 crossover.
“fat oxidation rate was significantly higher after 20 and 30 min of CLE (p < 0.05) ... cycling efficiency during TTE was significantly improved (p < 0.05) ... VAS significantly decreased post-exercise in the BCAA group (p < 0.05) ... insulin levels were significantly lower in the post-exercise period with supplemental BCAAs compared to placebo (p < 0.001)”
Source: PMID 40219047 · Luan 2025 · Nutrients
Dosage (research context · not a recommendation)
Common ergogenic supplementation: 5-20 g/day BCAA at a 2:1:1 leucine:isoleucine:valine ratio (≥2.5-3 g leucine per serving to approach the leucine threshold for MPS). Note: BCAA alone is inferior to a complete EAA/whole-protein dose for maximal muscle protein synthesis because the other essential amino acids become rate-limiting; standalone-BCAA ergogenic efficacy on performance/hypertrophy is contested in RCTs.
Regulatory Status · 4 Markets
- US · FDA
- Permitted dietary-supplement ingredient under DSHEA (structure/function claims with mandatory disclaimer); L-leucine/L-isoleucine/L-valine hold industry self-affirmed GRAS status (no individual FDA GRN), are usable for food fortification under the 21 CFR 172.320 amino-acid framework, and are permitted in infant formula (21 CFR 107.100). No FDA-authorized health claim.
- EU · EFSA
- Permitted for sale as a food-supplement ingredient under Directive 2002/46/EC; existing amino acids (not Novel Food). EFSA has issued NO authorized health claim for BCAA — exercise-performance, muscle and immune Article 13 claims were rejected (EFSA opinions 2010;1817 and 2011;2225).
- CN · China
- Permitted nutrient-fortification ingredient under SAMR: branched-chain amino acids (L-leucine/isoleucine/valine) listed in GB 14880-2012 food-fortifier standard and allowed in sports-nutrition foods (GB 24154); no health-function claim without registration.
- BR · ANVISA
- Permitted dietary-supplement ingredient in Brazil: L-leucine/L-isoleucine/L-valine listed in IN 28/2018 Anexo I (authorized amino-acid ingredients) and used within the sports-nutrition supplement framework (RDC 243/2018).
Safety
Generally well tolerated at typical supplemental doses; mild GI upset possible. Theoretical considerations at chronic high intakes include altered amino-acid balance and competition with tryptophan/aromatic amino acids. Caution in maple-syrup-urine disease (BCKDH defect) and in advanced liver/renal disease without medical supervision. Some cohort data associate elevated circulating BCAAs with insulin-resistance markers (association, not supplement-causation). Not intended to diagnose, treat, cure or prevent any disease.
Related
Goals: athletic-performance
Lifestyles: athletic-performance · senior-60-plus
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 41542879 · Aamann 2026 · Cochrane Database Syst Rev — Hepatic Encephalopathy in Cirrhosis
- PMID 36235655 · Martinho 2022 · Nutrients — Athletic Performance & Muscle Soreness
- PMID 36771225 · Chang 2023 · Nutrients — Sarcopenia / Muscle in Older Adults (Leucine-Enriched)
- PMID 26170041 · Bauer 2015 · J Am Med Dir Assoc — Muscle Mass & Physical Function in Older Adults (RCT)
- PMID 38404263 · Hey 2024 · Aliment Pharmacol Ther — Muscle / Sarcopenia in Cirrhosis (RCT — Null)
- PMID 40219047 · Luan 2025 · Nutrients — Exercise Substrate Metabolism & Post-Exercise Fatigue (RCT)
Frequently Asked Questions
1. Does taking BCAA actually improve athletic performance or build more muscle?
The research signal is weak for standalone BCAA. A systematic review of 24 athlete studies found the benefits on performance and body composition were negligible, even though BCAAs activated anabolic signalling and attenuated muscle soreness after resistance exercise (Martinho 2022, PMID 36235655). A key reason discussed in the literature is that BCAA alone lacks the other essential amino acids needed for maximal protein synthesis, so complete protein or full EAA is generally the more complete option. Treat BCAA as a recovery/soreness research context rather than a proven performance enhancer.
2. Is there any clinical population where BCAA has stronger evidence?
Yes — cirrhosis. The most recent Cochrane meta-analysis (18 trials, 934 adults) found BCAAs reduced hepatic encephalopathy (RR 0.79, 95% CI 0.64-0.96), though the certainty was rated low, and there was little to no effect on all-cause mortality (RR 0.89, 95% CI 0.71-1.12) with very low certainty (Aamann 2026, PMID 41542879). This is a managed-clinical-population finding under medical supervision, not a general-wellness claim, and asxan.ai reports it as evidence rather than treatment guidance.
3. What does the evidence show for older adults and muscle loss?
The evidence here is for leucine-enriched complete-protein formulas, not isolated BCAA. A meta-analysis of whey + leucine + vitamin D in sarcopenia (3 studies, 637 patients) found appendicular muscle mass improved, but handgrip strength and physical function (SPPB) only improved when supplementation was paired with exercise (Chang 2023, PMID 36771225). The PROVIDE RCT (380 adults, 13 weeks) showed a between-group gain of 0.17 kg appendicular muscle mass (P=.045) and a -1.01 second chair-stand improvement (P=.018), with handgrip and SPPB not differing between groups (Bauer 2015, PMID 26170041).
4. Are there honest negative findings worth knowing?
Yes. In a 12-month double-blind RCT in cirrhosis (150 volunteers), BCAA did not beat whey protein for muscle: no significant difference in grip strength (p = 0.29) or upper-limb lean mass (p = 0.22), and no benefit on physical frailty (Hey 2024, PMID 38404263). Combined with the negligible performance effect in athletes (Martinho 2022, PMID 36235655), the overall picture is that standalone BCAA's strongest verified benefit is in hepatic encephalopathy, while muscle/performance gains are inconsistent and often no better than complete protein.
Last evidence review: 2026-06-21